[
  {
    "ts": "2026-02-10T05:37:39+00:00",
    "headline": "5 Revealing Analyst Questions From Pfizer’s Q4 Earnings Call",
    "summary": "Pfizer closed the fourth quarter with revenue ahead of Wall Street expectations, but the market reacted negatively due to a combination of year-over-year sales decline and shrinking operating margins. Management explained that the drop in COVID-19 product demand weighed heavily on overall results, while non-COVID products delivered solid operational growth. CEO Albert Bourla cited the impact of a “narrow recommendation for vaccines in the US” as a driver behind lower COVID product sales and high",
    "url": "https://finance.yahoo.com/news/5-revealing-analyst-questions-pfizer-053739003.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "3280c393-c308-3873-ad26-3646c3149ba4",
      "content": {
        "id": "3280c393-c308-3873-ad26-3646c3149ba4",
        "contentType": "STORY",
        "title": "5 Revealing Analyst Questions From Pfizer’s Q4 Earnings Call",
        "description": "",
        "summary": "Pfizer closed the fourth quarter with revenue ahead of Wall Street expectations, but the market reacted negatively due to a combination of year-over-year sales decline and shrinking operating margins. Management explained that the drop in COVID-19 product demand weighed heavily on overall results, while non-COVID products delivered solid operational growth. CEO Albert Bourla cited the impact of a “narrow recommendation for vaccines in the US” as a driver behind lower COVID product sales and high",
        "pubDate": "2026-02-10T05:37:39Z",
        "displayTime": "2026-02-10T05:37:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "PFE Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o3tZoPUio75qXATbHoc_Hg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5rZqD7vIoFGnsFYAS_Ztw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-revealing-analyst-questions-pfizer-053739003.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-revealing-analyst-questions-pfizer-053739003.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T12:59:00+00:00",
    "headline": "Pfizer Becomes Newest Partner Added to BaseLaunch's Biotech Venture Incubator",
    "summary": "BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, announced today the pharmaceutical giant Pfizer has joined the Basel-based incubator, bringing the total number of leading pharma company partners to seven.",
    "url": "https://finance.yahoo.com/news/pfizer-becomes-newest-partner-added-125900969.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "6c8bb9b6-7c4a-3bae-bc05-49c7036f0309",
      "content": {
        "id": "6c8bb9b6-7c4a-3bae-bc05-49c7036f0309",
        "contentType": "STORY",
        "title": "Pfizer Becomes Newest Partner Added to BaseLaunch's Biotech Venture Incubator",
        "description": "",
        "summary": "BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, announced today the pharmaceutical giant Pfizer has joined the Basel-based incubator, bringing the total number of leading pharma company partners to seven.",
        "pubDate": "2026-02-10T12:59:00Z",
        "displayTime": "2026-02-10T12:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/e7c8c352b9195c16a1fdb2ecd2744510",
          "originalWidth": 400,
          "originalHeight": 209,
          "caption": "BaseLaunch is a Basel-based incubator that partners with scientists and entrepreneurs to help launch and grow exceptional biotech ventures developing cutting-edge therapeutics.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/biHuymTG15x51qFvubPEcw--~B/aD0yMDk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/e7c8c352b9195c16a1fdb2ecd2744510.cf.webp",
              "width": 400,
              "height": 209,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZMyTXtbbM9jz1GZOffmq5g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/e7c8c352b9195c16a1fdb2ecd2744510.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-becomes-newest-partner-added-125900969.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-becomes-newest-partner-added-125900969.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T15:39:36+00:00",
    "headline": "Pfizer Inc. (PFE) Announces FDA’s Grant of Priority Review for HYMPAVZI® (marstacimab) sBLA",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best healthcare stocks under $50 to invest in. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of hemophilia A […]",
    "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-announces-fda-153936181.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "3ee828e2-7f6a-3204-b37a-2d765d2ab270",
      "content": {
        "id": "3ee828e2-7f6a-3204-b37a-2d765d2ab270",
        "contentType": "STORY",
        "title": "Pfizer Inc. (PFE) Announces FDA’s Grant of Priority Review for HYMPAVZI® (marstacimab) sBLA",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the best healthcare stocks under $50 to invest in. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of hemophilia A […]",
        "pubDate": "2026-02-10T15:39:36Z",
        "displayTime": "2026-02-10T15:39:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Merck’s (MRK) Quality is Clear, but Growth Visibility Matters, TD Cowen Notes",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UKiv8LHLxutAA7dDIzr_pw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1v0rnd.QZj0de1gLzaNuAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-announces-fda-153936181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-announces-fda-153936181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T14:00:04+00:00",
    "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-trending-stock-140004432.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a44b0e39-290d-31a8-9f69-d2b17cb1c828",
      "content": {
        "id": "a44b0e39-290d-31a8-9f69-d2b17cb1c828",
        "contentType": "STORY",
        "title": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
        "description": "",
        "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
        "pubDate": "2026-02-10T14:00:04Z",
        "displayTime": "2026-02-10T14:00:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4",
          "originalWidth": 900,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/96m3P4v2KypZ_.2vXHQRKA--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4.cf.webp",
              "width": 900,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TvxSS8VO1p90iNVKrfS9eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-trending-stock-140004432.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-trending-stock-140004432.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T16:06:00+00:00",
    "headline": "Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line?",
    "summary": "BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.",
    "url": "https://finance.yahoo.com/news/bmys-legacy-portfolio-decline-weigh-160600522.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "863777e8-69de-3168-a3d8-ba6946351c90",
      "content": {
        "id": "863777e8-69de-3168-a3d8-ba6946351c90",
        "contentType": "STORY",
        "title": "Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line?",
        "description": "",
        "summary": "BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.",
        "pubDate": "2026-02-10T16:06:00Z",
        "displayTime": "2026-02-10T16:06:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmys-legacy-portfolio-decline-weigh-160600522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmys-legacy-portfolio-decline-weigh-160600522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T20:09:28+00:00",
    "headline": "Pfizer Pipeline Progress And Partnerships Tested Against Depressed Valuation",
    "summary": "Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced hemophilia patients. Partnered antifungal Cresemba reached sales in Asia Pacific that triggered a milestone payment to Pfizer. Pfizer joined the BaseLaunch biotech incubator as a partner to work with early stage drug developers. Pfizer enters this news cycle with its shares at $27.05 and a mixed return profile, with a 13.6% gain over the past year, a 25.9% decline over three...",
    "url": "https://finance.yahoo.com/news/pfizer-pipeline-progress-partnerships-tested-200928544.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d9ed92dd-a1e4-3e36-9d98-2c196f430ec4",
      "content": {
        "id": "d9ed92dd-a1e4-3e36-9d98-2c196f430ec4",
        "contentType": "STORY",
        "title": "Pfizer Pipeline Progress And Partnerships Tested Against Depressed Valuation",
        "description": "",
        "summary": "Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced hemophilia patients. Partnered antifungal Cresemba reached sales in Asia Pacific that triggered a milestone payment to Pfizer. Pfizer joined the BaseLaunch biotech incubator as a partner to work with early stage drug developers. Pfizer enters this news cycle with its shares at $27.05 and a mixed return profile, with a 13.6% gain over the past year, a 25.9% decline over three...",
        "pubDate": "2026-02-10T20:09:28Z",
        "displayTime": "2026-02-10T20:09:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pipeline-progress-partnerships-tested-200928544.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pipeline-progress-partnerships-tested-200928544.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T21:51:00+00:00",
    "headline": "Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway.",
    "summary": "Less than two months into 2026, shares of  Gilead Sciences  are already outpacing some of the most talked-about pharmaceutical companies.  After the closing bell, the biopharmaceutical company posted adjusted earnings of $1.86 a share, which outstripped analysts’ calls for $1.81.  Gilead attributed the change to higher sales of HIV and liver-disease products, which were partially offset by lower sales of Veklury, its Covid-19 antiviral.",
    "url": "https://www.barrons.com/articles/gilead-earnings-stock-price-f1f36bf5?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "8a748589-aea8-3e07-a0d3-cb4d585b2ae3",
      "content": {
        "id": "8a748589-aea8-3e07-a0d3-cb4d585b2ae3",
        "contentType": "STORY",
        "title": "Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway.",
        "description": "",
        "summary": "Less than two months into 2026, shares of  Gilead Sciences  are already outpacing some of the most talked-about pharmaceutical companies.  After the closing bell, the biopharmaceutical company posted adjusted earnings of $1.86 a share, which outstripped analysts’ calls for $1.81.  Gilead attributed the change to higher sales of HIV and liver-disease products, which were partially offset by lower sales of Veklury, its Covid-19 antiviral.",
        "pubDate": "2026-02-10T21:51:00Z",
        "displayTime": "2026-02-10T21:51:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8a748589-aea8-3e07-a0d3-cb4d585b2ae3/gilead-earnings-surprise-why.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/89f489d64b0a92a4a22fd03aa27f2b15",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X078vvJXUIiLEBq8utnocA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/89f489d64b0a92a4a22fd03aa27f2b15.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cpMrX8Jl6P9ldyk1tq3_og--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/89f489d64b0a92a4a22fd03aa27f2b15.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/gilead-earnings-stock-price-f1f36bf5?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T22:31:00+00:00",
    "headline": "PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight",
    "summary": "DelveInsight's PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), and others. The selected indications are based on approved therapies and ongoing pipeline",
    "url": "https://finance.yahoo.com/news/protac-market-shows-accelerated-growth-223100028.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "28eed66c-725e-3fbc-8a4e-23abb25213f9",
      "content": {
        "id": "28eed66c-725e-3fbc-8a4e-23abb25213f9",
        "contentType": "STORY",
        "title": "PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight",
        "description": "",
        "summary": "DelveInsight's PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), and others. The selected indications are based on approved therapies and ongoing pipeline",
        "pubDate": "2026-02-10T22:31:00Z",
        "displayTime": "2026-02-10T22:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/9711e6be91b3534a074e21a35fd57d95",
          "originalWidth": 400,
          "originalHeight": 181,
          "caption": "DelveInsight Logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KAOnJnJW7AvXzb_irAdD3w--~B/aD0xODE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9711e6be91b3534a074e21a35fd57d95.cf.webp",
              "width": 400,
              "height": 181,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/b5Q8EO062JYIoob3yognYQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9711e6be91b3534a074e21a35fd57d95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/protac-market-shows-accelerated-growth-223100028.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/protac-market-shows-accelerated-growth-223100028.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "ALPMF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]